For much of the last decade, healthcare AI has been evaluated like a technology story. Investors focused on model performance. Founders competed on accuracy. Health systems asked whether an algorithm could outperform existing workflows. Those factors still matter. But they are becoming less differentiating. Open-source models, foundation models, and increasingly…
Read More
Computational and preclinical data support advancement of LTS-201 and LTS-101 programs into clinic later this year Latus founder Beverly Davidson, Ph.D., awarded the ASGCT Outstanding Achievement Award – the Society’s highest honor PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a company advancing scalable genetic medicines for broad patient populations, today…
Read More
Presentation details the IND-enabling work for IMGS-203, a potent Stimulator of Interferon Genes (STING) Agonist, for the treatment of Glioblastoma Multiforme (GBM) Houston, Texas, April 15, 2026 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that it will present a poster at the upcoming American…
Read More
Leveraging AI-Driven Multiomics and Spatial Biology to Unlock the Full Potential of Next-Generation Cytotoxic Dual Checkpoint Inhibitor WALTHAM, Mass. & HOUSTON--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced a strategic partnership to accelerate…
Read More
Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM),…
Read More
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience Analytics PHILADELPHIA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Atalan, the world’s first Clinical Retention Intelligence (CRI) platform, today announced a strategic partnership with Accrete Health Partners, the venture arm of Bon Secours…
Read More
IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Houston, Texas, Dec. 4, 2025 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded…
Read More
LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore the potential of LTS-101 to address a high unmet medical need PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company…
Read More
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning (AI/ML) strategy and the addition of two world-class scientific advisors: Pranam Chatterjee, PhD (University of Pennsylvania) and Philip M. Kim, PhD (University…
Read More
Healthcare is entering a new era filled with opportunity. Hospitals are exploring smarter ways to care for patients with the staff they have. Pharmaceutical companies are rethinking how to bring therapies to market with greater speed and precision. Across the industry, one theme is clear: AI-powered automation and data are…
Read More